KRT24 Antibody (C-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q2M2I5 |
---|---|
Clone Names | 91230116 |
Gene ID | 192666 |
---|---|
Other Names | Keratin, type I cytoskeletal 24, Cytokeratin-24, CK-24, Keratin-24, K24, Type I keratin-24, KRT24, KA24 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP13368b was selected from the C-term region of KRT24. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | KRT24 |
---|---|
Synonyms | KA24 |
Tissue Location | Highly expressed in keratinocytes, placenta, colon and spleen. Expressed at lower level in thymus and testis |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes a member of the type I (acidic) keratinfamily, which belongs to the superfamily of intermediate filament(IF) proteins. Keratins are heteropolymeric structural proteinswhich form the intermediate filament. These filaments, along withactin microfilaments and microtubules, compose the cytoskeleton ofepithelial cells. The type I keratin genes are clustered in aregion of chromosome 17q12-q21.
References
Hong, Y., et al. Clin. Cancer Res. 13(4):1107-1114(2007)Schweizer, J., et al. J. Cell Biol. 174(2):169-174(2006)Sprecher, E., et al. J. Invest. Dermatol. 119(3):692-698(2002)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.